|Bid||55.00 x 800|
|Ask||55.87 x 2200|
|Day's Range||54.72 - 57.46|
|52 Week Range||30.02 - 58.72|
|Beta (5Y Monthly)||1.43|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
We feel now is a pretty good time to analyse ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) business as it appears the...
The Pfizer (PFE)vaccine news does not take away the need for rapid testing, since it may be a year before vaccines are available to all risk groups notes Brian Weinstein, a health-care sector analyst at William Blair. Plus it’s not clear how many people will use the vaccine, because of safety concerns, says Deutsche Bank market strategist Marion Laboure. The good news is that Biden will likely preserve and expand the Affordable Care Act which is good for biopharma companies, notes Jefferies analyst Peter Welford.
ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid. Stock dips in after-hours trading.